A Mectizan Expert Committee (MEC) Statement on the use of Mectizan® during the COVID-19 pandemic
Click here to read more
Cliquez ici pour lire en français
Haga clic aquí para leer en español
Clique aqui para ler em portugues
News, videos & resources
Get the latest on the Mectizan Donation Program
Report
Reaching the Criteria to Stop Onchocerciasis Mass Drug Administration: Ethiopia, Nigeria, and Uganda Pave the Way
Part of the Act to End NTDS | East technical brief series June 2021.
To eliminate human onchocerciasis transmission of the filarial parasite Onchocerca volvulus (OV), endemic countries undertake a multi-step processi to: 1.
Reaching the criteria to stop OV MDA (9.30 MB)Annual Highlights
2020 Mectizan Donation Program Annual Highlights (English) | Faits saillants de l’année 2020 du PDM (édition française)
MDP 2020: Investing for Impact. This publication summarizes the accomplishments of the Mectizan Donation Program and its partners in 2020.
PDM 2020: Investir pour l’impact.
Mectizan-Donation-Program-Annual-Highlights-2020-English (3.81 MB)MDP Newsletter
Mectizan Program Notes – Spring 2021
Welcome to a new season in the campaign to eliminate river blindness and elephantiasis. Although the events of last year put many obstacles in our path, below you will find news of progress made thanks to the determination of all partners to continue the fight to #StampOutOncho and #eliminateLF from the planet.
Mectizan Expert Committee Statement on Mectizan Use During the COVID-19 Pandemic
A Mectizan Expert Committee (MEC) Statement on the use of Mectizan® during the COVID-19 pandemic: The MEC reminds country partners that Mectizan is donated only for the elimination of onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis).Declaración del Comité de Expertos de Mectizan (MEC) sobre el uso de Mectizan®
Declaración del Comité de Expertos de Mectizan (MEC) sobre el uso de Mectizan®: El MEC recuerda a los países socios que Mectizan es donado únicamente para la eliminación de la oncocercosis (ceguera de los ríos) y la filariasis linfática (elefantiasis)La pandemia de COVID-19 ha despertado el interés de los medios de comunicación y un incremento de las publicaciones sobre la acción de la ivermectina en la replicación viral del SARS-Cov-2.